ArticleInflammopharmacology2026
Anti-acne cinnamic acid bigel: a hybrid topical system for concurrent modulation of inflammation and microbial load.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcne vulgaris is a chronic inflammatory skin disease aggravated by Cutibacterium acnes (P. acnes). Conventional drug delivery treatments researchers reported irritation, resistance and poor efficacy. Poor skin permeability, along with oxidative degradation hindering its efficacy on Dermal drug delivery application. PURPOSE: In this study, the novel work was to incorporate and optimize cinnamic acid phytoconstituent within a bigel system to improve solubility, stability, permeation and achieve prolonged release. STUDY
designBox-Behnken design was used to optimize formulation, independent variables (oleogel: hydrogel ratio, mixing time and mixing or rotation speed) with globule size, hardness and in vitro drug release as responses.
methodsCinnamic acid-loaded bigels were prepared by phase mixing of hydrogel and oleogel components at varying ratios and optimized using a Box-Behnken design. Formulations were evaluated for viscosity and drug content, and the optimized batch (F7) was further characterized by FTIR, DSC, SEM, rheological analysis, amplitude sweep stability, antibacterial activity against P. acnes and P. aeruginosa, anti-inflammatory activity, and ex vivo skin permeation.
resultsThe optimized formulation exhibited a globule size of 619 nm and a zeta potential of - 30.6 mV, indicating good stability. In vitro drug release reached 69.98 ± 0.534% over 6 h, compared to 95.02 ± 1.3% for the marketed formulation, following Korsmeyer-Peppas kinetics (R
Indexed as
Identifiers
42243562What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.